Low plasma levels of the soluble receptor for advanced glycation end products in HIV-infected patients with subclinical carotid atherosclerosis receiving combined antiretroviral therapy

Atherosclerosis

Volumn 219, Issue 2, 2011, Pages 778-783

  Jeong, Su Jin ^a   Kim, Chang Oh ^a   Song, Young Goo ^a   Baek, Ji hyeon ^a   Kim, Sun Bean ^a   Jin, Sung Joon ^a   Ku, Nam Su ^a   Han, Sang Hoon ^a   Choi, Jun Yong ^a   Lee, Hyun Chul ^a   Kim, June Myung ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Atherosclerosis; Carotid artery intima media thickness; Combined antiretroviral therapy; HIV infection; Soluble receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTIRETROVIRUS AGENT; CHOLESTEROL; GLUCOSE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTERIAL WALL THICKNESS; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; WAIST HIP RATIO;

ADULT; ANALYSIS OF VARIANCE; ANTI-RETROVIRAL AGENTS; ASYMPTOMATIC DISEASES; BIOLOGICAL MARKERS; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; DOWN-REGULATION; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, IMMUNOLOGIC; REPUBLIC OF KOREA; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TUNICA INTIMA; TUNICA MEDIA;

EID: 82955247819     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.08.003     Document Type: Article

References (41)

1. Palella F.J., Delaney K.M., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New Engl J Med 1998, 338:853-860.
2. Guaraldi G., Stentarelli C., Zona S., et al. Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects. Atherosclerosis 2010, 208:222-227.
3. Friis-Mller N., Sabin C.A., Weber R., et al. Combination antiretroviral therapy and the risk of myocardial infarction. New Engl J Med 2003, 349:1993-2003.
4. Francisci D., Giannini S., Baldelli F., et al. HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction. AIDS 2009, 23:589-596.
5. Hsue P.Y., Hunt P.W., Schnell A., et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009, 23:1059-1067.
6. Vlassara H., Bucala R., Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 1994, 70:138-151.
7. Dyer D.G., Blackledge J.A., Thorpe S.R., et al. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 1991, 266:11654-11660.
8. Yonekura H., Yamamoto Y., Sakurai S., et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003, 370:1097-1109.
9. Hudson B.I., Harja E., Moser B., et al. Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease: the next C-reactive protein?. Arterioscler Thromb Vasc Biol 2005, 25:879-882.
10. Geroldi D., Falcone C., Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem 2006, 13:1971-1978.
11. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
12. Reznikov L.L., Waksman J., Azam T., et al. Effect of advanced glycation end products on endotoxin-induced TNF-alpha, IL-1beta and IL-8 in human peripheral blood mononuclear cells. Clin Nephrol 2004, 61:324-336.
13. Yan S.D., Schmidt A.M., Anderson G.M., et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994, 269:9889-9897.
14. Schmidt A.M., Stern D. Atherosclerosis and diabetes: the RAGE connection. Curr Atheroscler Rep 2000, 2:430-436.
15. Park L., Raman K.G., Lee K.J., et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998, 4:1025-1031.
16. Bucciarelli L.G., Wendt T., Qu W., et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002, 106:2827-2835.
17. Falcone C., Emanuele E., D'Angelo A., et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005, 25:1032-1037.
18. Koyama H., Shoji T., Yokoyama H., et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005, 25:2587-2593.
19. Basta G., Castagnini M., Del Turco S., et al. High plasma levels of the soluble receptor for advanced glycation endproducts in patients with symptomatic carotid atherosclerosis. Eur J Clin Invest 2009, 39:1065-1072.
20. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
21. Pignoli P., Tremoli E., Poli A., et al. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986, 74:1399-1406.
22. Yanase T., Nasu S., Mukuta Y., et al. Evaluation of a new carotid intima-media thickness measurement by B-mode ultrasonography using an innovative measurement software, intimascope. Am J Hypertens 2006, 19:1206-1212.
23. Stein J.H., Korcarz C.E., Post W.S. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: summary and discussion of the American Society of Echocardiography consensus statement. Prev Cardiol 2009, 12:34-38.
24. O'Leary D.H., Polak J.F., Kronmal R.A., et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. New Engl J Med 1999, 340:14-22.
25. Humpert P.M., Djuric Z., Kopf S., et al. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 2007, 6:9.
26. Yamagishi S., Adachi H., Nakamura K., et al. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 2006, 55:1227-1231.
27. Pullerits R., Brisslert M., Jonsson I., et al. Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via beta2 integrin Mac-1. Arthritis Rheum 2006, 54:3898-3907.
28. Friis-Mller N., Reiss P., Sabin C.A., et al. Class of antiretroviral drugs and the risk of myocardial infarction. New Engl J Med 2007, 356:1723-1735.
29. Hsue P.Y., Lo J.C., Franklin A., et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004, 109:1603-1608.
30. Dub M.P., Johnson D.L., Currier J.S., et al. Protease inhibitor-associated hyperglycaemia. Lancet 1997, 350:713-714.
31. Carr A., Samaras K., Burton S., et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
32. Lakatta E.G., Wang M., Najjar S. Arterial aging and subclinical arterial disease are fundamentally intertwined at macroscopic and molecular levels. Med Clin North Am 2009, 93:583-604. [table of contents].
33. Schillaci G., De Socio G.V., Pirro M., et al. Impact of treatment with protease inhibitors on aortic stiffness in adult patients with human immunodeficiency virus infection. Arterioscler Thromb Vasc Biol 2005, 25:2381-2385.
34. McVeigh G.E., Morgan D.J., Finkelstein S.M., et al. Vascular abnormalities associated with long-term cigarette smoking identified by arterial waveform analysis. Am J Med 1997, 102:227-231.
35. Van Bortel L.M., Duprez D., Starmans-Kool M.J., et al. Clinical applications of arterial stiffness, task force. III. Recommendations for user procedures. Am J Hypertens 2002, 15:445-452.
36. van Leuven S.I., Sankatsing R., Vermeulen J.N., et al. Atherosclerotic vascular disease in HIV: it is not just antiretroviral therapy that hurts the heart!. Curr Opin HIV AIDS 2007, 2:324-331.
37. + T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS 2008, 22:1615-1624.
38. Geroldi D., Falcone C., Emanuele E., et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens 2005, 23:1725-1729.
39. Sakurai S., Yamamoto Y., Tamei H., et al. Development of an ELISA for esRAGE and its application to type 1 diabetic patients. Diabetes Res Clin Pract 2006, 73:158-165.
40. Katakami N., Matsuhisa M., Kaneto H., et al. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care 2005, 28:2716-2721.
41. Lekakis J., Tsiodras S., Ikonomidis I., et al. HIV-positive patients treated with protease inhibitors have vascular changes resembling those observed in atherosclerotic cardiovascular disease. Clin Sci 2008, 115:189-196.